Ionis reports third quarter financial results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil rally pressures S&P, Nasdaq; Microsoft, Salesforce buoy Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Lumentum shares fall after hitting 52-week high
Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 39c; Offers F22 Revenue Guidance
November 9, 2022 7:03 AM ESTIonis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($0.33), $0.39 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $160 million versus the consensus estimate of $145.75 million.
GUIDANCE:
Ionis Pharmaceuticals sees FY2022 revenue of $575 million, versus the consensus of $595... More



